Oncternal Therapeutics Inc. buy Brookline Capital Management
Start price
11.03.23
/
50%
€0.70
Target price
11.03.24
-
Performance (%)
-62.03%
End price
12.03.24
-
Summary
This prediction is currently being closed. The BUY prediction by Brookline_Capital_Ma for Oncternal Therapeutics Inc. is performing very badly with a performance of -62.03%. Brookline_Capital_Ma has a follow-up prediction for Oncternal Therapeutics Inc. where he still thinks Oncternal Therapeutics Inc. is a Buy. Brookline_Capital_Ma has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Oncternal Therapeutics Inc. | - | - | - |
| iShares Core DAX® | 3.178% | 0.980% | 15.331% |
| iShares Nasdaq 100 | 2.972% | 0.925% | 39.831% |
| iShares Nikkei 225® | 0.545% | -4.556% | 17.661% |
| iShares S&P 500 | 2.367% | 0.833% | 30.000% |
Comments by Brookline_Capital_Ma for this prediction
In the thread Oncternal Therapeutics Inc. diskutieren
Oncternal Therapeutics, Inc. (NASDAQ: ONCT) had its "buy" rating re-affirmed by analysts at Brookline Capital Management.
Ratings data for ONCT provided by MarketBeat
In the thread Trading Oncternal Therapeutics Inc.
Die von Brookline_Capital_Ma gewählte maximale Laufzeit wurde überschritten
Current prediction by Brookline_Capital_Ma for Oncternal Therapeutics Inc.
Oncternal Therapeutics Inc.
Start price
Target price
Perf. (%)
€0.31
04.12.23
04.12.23
€1.85
04.12.24
04.12.24
3.23%
05.01.24
05.01.24
